{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-010486","form_type":"8-K","ticker":"SNDX","cik":"0001395937","company_name":"Syndax Pharmaceuticals Inc","filed_at":"2026-01-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:34.979894+00:00","generated_at":"2026-05-16T10:49:01.561003+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Syndax reports preliminary 2025 Revuforj $125M, Niktimvo $152M net rev, cash $394M","bullets":["Revuforj preliminary net revenue $44M (Q4) and $125M (FY), up 38% QoQ.","Niktimvo preliminary net revenue $56M (Q4) and $152M (FY); Syndax's 50% profit share expected ~25-30% of net rev.","Cash, equivalents and marketable securities ~$394M at year-end 2025 (unaudited).","2026 R&D + SG&A expense guidance ~$400M (excl. $50M non-cash stock comp); company funded to profitability.","Key 2026 milestones: complete IPF trial enrollment, advance frontline Phase 3 revumenib trials, initiate MF proof-of-principle."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-010486","json":"https://secwatch.observer/filing/0001193125-26-010486.json","markdown":"https://secwatch.observer/filing/0001193125-26-010486.md","text":"https://secwatch.observer/filing/0001193125-26-010486.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1395937/000119312526010486/0001193125-26-010486-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1395937/000119312526010486/sndx-20260112.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T10:49:01.561003+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}